In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Something old, something new, something biobased: Designer grows a mushroom wedding gown
In the Netherlands, designer Dasha Tsapenko “grew” her wedding dress using mycelium and vintage linen lace sourced from Ukrainian flea markets.
“I wanted to combine...
Italy team develops biobased, inflammation-busting burn bandages
In Italy, a team from Istituto Italiano di Tecnologia has developed a biodegradable and biocompatible bandage using plant-based materials such as maize, pectin, and...
Swiss startup Nectariss recreates bougie fungi with fermentation
In Switzerland, a startup is recreating the intensely umami flavor of truffles, a pricey fungi that is impossible to cultivate and so difficult to...